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Abstract
Background: Little is known about the efficiency and effectiveness of the current level of diabetes screening
activity in Ontario where there is universal access to health services. Our study aims were to: (i) determine how
often Ontarians are screened for diabetes; (ii) estimate screening efficiency based on the number needed to screen
(NNS) to diagnosis one diabetes case; (iii) examine the population effectiveness of screening as estimated by the
number of undiagnosed diabetes cases.
Methods: Ontario respondents of the Canadian Community Health Survey who agreed to have their responses
linked to health care data (n = 37,400) provided the cohort. The five-year probabilities of glucose testing and
diabetes diagnoses were estimated using a Cox Proportional Hazards Model. We defined NNS as the ratio of
diabetes tests to number of diabetes diagnoses over the study period. We estimated the number of undiagnosed
diabetes by dividing the number not tested at the end of study period by the NNS.
Results: 80% of women and 66% of men had a blood glucose test within 5 years. The efficiency of screening was
estimated by a NNS of 14 among men and 22 among women. 127,100 cases of undiagnosed diabetes were
estimated, representing 1.4% of the Ontario adult population. Increasing age, hypertension, immigrant and non-
white ethnicity, and number of general practitioner visits were associated with an increased likelihood of having a
glucose test (LR c2 p < 0.001). Low income men were less likely to be tested.
Conclusions: Diabetes screening was high in this population-based cohort of Ontarians. Screening efficiency varied
considerably in the population. Undiagnosed diabetes continues to be prevalent and remains concentrated in the
highest risk groups for diabetes, especially among men.
Background
The global burden of diabetes is increasing and has been
well documented [1-3]. In addition to its large disease
burden, evidence suggests that one-third to one-half of
all diabetes cases continue to be ‘undiagnosed’ in indus-
trialized settings [4-9]. These estimates come from
population health surveys that compare physiologic
measures [fasting blood glucose or oral glucose toler-
ance test results] with respondents’ self-report of dia-
betes. These surveys are resource intensive and as a
consequence, few countries implement them on an
ongoing basis with some exceptions [4,5].
Type 2 diabetes (diabetes) can remain asymptomatic
for up to 10 years [10], and at the time of diagnosis 20-
30% will have already developed complications [11,12].
Early detection and treatment of diabetes through
screening has been proposed to prevent or slow the
development of microvascular and macrovascular com-
plications [13,14]. In Canada there is no formal diabetes
screening program or policy. However, two clinical
guidelines provide directions for screening. Since 1998,
the Canadian Diabetes Association (CDA) has recom-
mended screening individuals aged 45 years and older
every three years with a fasting blood glucose test, and
earlier and/or more frequently for individuals with risk
factors [15-17]. The age to initiate screening was
reduced to 40 in the 2003 CDA guidelines [16]. These
recommendations were predominantly consensus-driven,
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screening (Grade D). The Canadian Task Force on Pre-
ventive Health Care (CTFPHC) [18] recommends
screening only for adults with established hypertension
or hyperlipidemia, for whom benefits of early diabetes
detection and treatment have been shown.
Although glucose testing has increased significantly
among Ontarians since these guidelines were implemen-
ted [19], little is known about the efficiency and effec-
tiveness of the current level of diabetes screening
activity in Ontario where there is universal access to
health services. Estimates on the burden of undiagnosed
diabetes in Canada are extrapolated from data from
other industrialized countries.
Using population-based Ontario databases, our objec-
tives were to (i) determine how often people are
screened for diabetes in the overall Ontario population
and in different at-risk groups; (ii) estimate Ontario’s
screening efficiency based on the number needed to
screen (NNS) to diagnose one case of diabetes; and (iii)
examine the population effectiveness of screening as
estimated by the number of Ontarians with undiagnosed
diabetes.
Methods
Cohort definition
Ontario respondents of the 2000/2001 Canadian Com-
munity Health Survey (CCHS, Cycle 1.1) [20] who
agreed to have their data linked to Ontario Health
Insurance Plan (OHIP) billing data provided the base
cohort. Ninety-one percent of Ontario respondents
agreed to have their data linked (n = 37,400). Ontario is
Canada’s most populated province with an ethnically
diverse population of 12.7 million in 2006 [21]. The
CCHS is a representative national survey administered
by Statistics Canada on an annual basis to collect infor-
mation on self-perceived health, chronic conditions,
socio-demographic and socio-economic information on
community dwelling adults and adolescents aged 12 and
over [20]. Responding to the survey is voluntary and
data are collected directly from survey respondents.
Those living on Indian Reserves and Crown Lands, insti-
tutional residents, full-time members of the Canadian
Armed Forces, and residents of certain remote areas are
excluded from the sampling frame. The CCHS uses the
area frame of Canada’s Labour Force Survey for sam-
pling which excludes persons living on reserves and
other Aboriginal settlements in the provinces, full-time
members of the Canadian Armed Forces and the institu-
tionalized population [22]. The survey uses a multistage
stratified cluster design and provides cross-sectional
data representative of 98% of the Canadian population
over the age of 12 years and attained a national
response rate of 84.7% for the 2000/2001 cycle [20].
Individuals were excluded if, at the time of survey
completion (September 1, 2000 to November 30, 2001),
they were less than 20 years of age, had a physician
diagnosis of diabetes defined by inclusion in the Ontario
Diabetes Database [23], self-reported pregnancy, or were
ineligible for OHIP services at any point in the
12 months prior to survey completion. The Ontario Dia-
betes Database is a cumulative diabetes registry that
uses administrative health records to determine diabetes
status. A detailed description of its methodology can be
found elsewhere [23].
Data sources
After our cohort was created using the CCHS survey data-
base, data for each individual were linked to administrative
health databases that include records for all individuals eli-
gible for health services under the government-funded
Ontario Health Insurance Plan (OHIP), using unique
encrypted health card numbers. Individual-level data from
each Ontario CCHS respondent in the cohort was deter-
ministically linked to individual-level information on
health services accessed through OHIP and to other
administrative health databases. The OHIP database was
used to identify laboratory service claims for diabetes test-
ing. All Ontario residents are eligible for coverage by
OHIP after 3 months of residency in the province. Legisla-
tion prohibits the private delivery of services covered
under OHIP, including laboratory testing.
The diabetes status of respondents was established by
linking individuals to the Ontario Diabetes Database
(ODD), which contains all patients said to have physi-
cian-diagnosed diabetes identified since 1991 and their
date of diagnosis on the basis of administrative health
data. An individual is said to have physician-diagnosed
diabetes if at least one of the following criteria are met:
(i) hospital admission with a diabetes diagnosis; (ii) a
physician services claim with a diabetes diagnosis fol-
lowed within 24 months by either a further physician
service claim or a hospital admission with a diabetes
diagnosis. A hospital record with a diagnosis or preg-
n a n c yc a r eo rd e l i v e r yc l o s et oad i a b e t i cr e c o r d( e g9 0
days before and 120 days after the diabetes record date)
is considered to relate to gestational diabetes and is not
included in the ODD. The ODD has been validated
against primary-care records and demonstrated to be
accurate for determining the incidence and prevalence
of diabetes (sensitivity 86%, specificity 97%) [23,24]. Elig-
ibility for OHIP health services and information on
deaths was captured from the Registered Person Data-
base (RPD) and self-reported demographic information
was derived from the CCHS. Data from April 1, 2001 to
March 31, 2006 were extracted for analysis. All data
extraction and analyses were carried out using SAS
(Version 9.1).
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Information on socio-demographic characteristics and
self-reported health states was available from the CCHS.
These variables included age, sex, urban/rural address,
income quartiles, education quartiles, ethnicity, immi-
grant status, current smoking, self-reported heart dis-
ease, self-reported hypertension and derived body mass
index (BMI) from self-reported weight and height.
A binary variable was derived to indicate whether an
individual met the CDA recommendations for screening.
If an individual met any one of the following criteria:
age > 40, non-white ethnicity, self reported heart dis-
ease, or self-reported hypertension, they were considered
to be meet the CDA recommendations for screening.
Using the OHIP database, the number of general practi-
tioner/family physician (GP/FP) visits and the number
of specialist visits (non-primary care providers) that
occurred in the twelve months prior to survey comple-
tion was determined for each individual. The 5-year risk
of developing diabetes was determined using the Dia-
betes Population Risk Tool (DPoRT) aggregated into
deciles of risk. DPoRT is a validated population-based
risk tool developed in Ontario to predict incidence of
physician-diagnosed diabetes for up to a 10-year time
period using the variables in the CCHS [25,26]. The pre-
dictive factors included in the DPoRT algorithm are
BMI, age, ethnicity, hypertension, immigrant status,
smoking, education status and heart disease [25,26]. The
algorithm has high discrimination (C = 0.8) and accu-
racy and has been validated in 2 external populations
including the cohort used in this study. A separate pub-
lication describes the development and validation of this
population-level risk algorithm in greater detail [26].
Survival analysis
Members of the study cohort were deterministically
linked to OHIP fee codes for serum blood glucose
(SBG) laboratory tests using unique encrypted health
card numbers (OHIP codes G002, L111, L112) [27]. No
OHIP fee code discriminates between fasting and ran-
dom serum blood glucose measurement. We have pre-
viously demonstrated that the SBG is the most common
laboratory test used to identify diabetes in Ontario,
representing 87% of all diabetes-related laboratory tests
(among SBG, HbA1c, and oral glucose tolerance tests)
u n d e r g o n eb yi n d i v i d u a l sw i thout a pre-existing physi-
cian-diagnosis of diabetes in the year 2005 [19]. We
have also previously demonstrated that oral glucose tol-
erance tests are rarely used in Ontario with fewer than
2500 tests ordered in the year 2005 among an adult
population size exceeding 9 million [19]. Survival analy-
sis was selected as the analytic approach to investigate
diabetes testing over a five year time period, and at the
same time examine diabetes incidence in the same
cohort. Respondents were followed from the time of
their individual CCHS 1.1 survey completion date (Sep-
tember 1, 2000-November 30, 2001) until their first
SBG test, diabetes diagnosis date or end of study period
(March 31, 2006). Diabetes diagnosis was defined by
date of entry into the ODD. This date is the same as
the date of an individual’s contact with the health sys-
tem that met the criteria for diabetes diagnosis under
the ODD algorithm. The following events were used to
right censor further individual data: a date of death as
recorded in the RPDB, and cessation of OHIP eligibility
during the observation period as defined by no OHIP
eligibility for a full fiscal year. The midpoint of the fiscal
year (October 1) was used as the time point when elig-
ibility was considered to have ended. Time to SBG test-
ing was estimated using a Cox Proportional Hazards
Model. All estimates were calculated using bootstrap
survey weights to accurately reflect the demographics of
the Ontario population.
Measures of efficiency and population effectiveness of
diabetes screening
We defined the efficiency of screening as the ratio of the
number of screening tests for diabetes to the number of
diabetes diagnoses. We used the term ‘number needed
to screen’ (NNS) to represent screening efficiency. To
compute ‘number needed to screen’ the number of indi-
viduals tested with a SBG over the five year study period
was divided by the number of incident diabetes cases
that accrued during the same period (NNS = number of
individuals tested with at least one SBG test over 5
years/the number of individuals with new diabetes diag-
noses over 5 years). The purpose of this term is to cap-
ture the efficiency of testing in different at-risk groups.
We defined the population effectiveness of screening as
the magnitude of undiagnosed cases of diabetes at the
end of the study period. The number of individuals with
undiagnosed diabetes was estimated by dividing the
number of individuals not tested with a SBG at the end
of five years by the ‘number needed to screen’ (number
with undiagnosed diabetes = N - number of individuals
tested by 5 years/NNS). The measure of ‘undiagnosed
diabetes’ is an estimate of how many additional cases of
diabetes would be detected in a scenario of 100%
screening. Both NNS and the number of ‘undiagnosed’
diabetes cases were calculated for each covariate, and its
varying levels of risk.
Research ethics
Ethics approval was granted from the institutional
review board at Sunnybrook Health Sciences Centre,
Toronto, Ontario, Canada.
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Rates and Predictors of glucose testing
The baseline characteristics of our cohort are presented
in Table 1. At the end of the five-year study period,
over 80% of women and 66% of men underwent a SBG
test between 2001 and 2006 (Table 2). In adults aged 40
and over, 84% of women and 63% of men underwent
diabetes testing.
Among women, the groups observed to have the high-
est rates of testing were those in the highest (tenth dec-
ile) diabetes risk group (89.9%), those with self-reported
hypertension (89.4%), self-reported heart disease (88.6%)
and those with more than six primary care visits in the
year preceding CCHS survey completion (88.5%).
Among men, the highest rates of testing were observed
in men aged 80 and over (86.3%), those with self-
reported hypertension (85.8%), and those with more
than six primary care visits in the year prior to the sur-
vey (84.8%).
Among women, increasing age, increasing BMI, hyper-
tension, immigrant status, non-white ethnicity, and
number of GP visits were all associated with a signifi-
cantly increased likelihood of having a SBG test in the
multivariate survival model (LR c2p<0 . 0 0 1 )( T a b l e3 ) .
Among men, the same factors were significantly asso-
ciated with an increased likelihood of undergoing a SBG
test, with the exception of increasing BMI which was at
the margins of significance (adjusted HR 1.01, 95% CI
1.00-1.02). Men with low incomes were significantly less
likely to undergo SBG testing (adjusted HR 0.86, 95% CI
0.75-0.98). Among women, those who did not self-
report income were significantly less likely to undergo
an SBG (adjusted HR 0.88, 95% CI 0.79-0.98) while low
income women were no more or less likely to undergo
testing. The probability of SBG testing increased with
age for both men and women, but increasing age
appeared to be a more powerful determinant of SBG
testing for men (Table 3).
Figures 1 and 2 depict the relationship between SBG
testing and the five-year risk of diabetes for men and
women. In both sexes there is a tendency towards
greater observed testing with increased risk of diabetes
with higher rates of screening observed among women,
across all deciles of diabetes risk.
Efficiency of Diabetes Testing
Upon conclusion of the five year study period, the
observed incidence rate of diabetes was 4.7% among
men and 3.7% among women in this cohort (Table 1,
Table 2). In men, the highest diabetes incidence rates
were observed among those with the highest (tenth dec-
ile) predicted diabetes risk (19.2%), those with a BMI
>35 (18.2%), self-reported heart disease (12.3%), those
age 70-80 years (11.4%), and self-reported hypertension
(11.3%). Similar findings were seen in women (Table 2).
We used the summary statistic of ‘number needed to
screen’ (NNS) to capture the efficiency of screening in
different groups. Only 14 men and 22 women required
screening in order to detect an incident case of diabetes
respectively, in the overall Ontario population. The
highest yield of testing was seen among those with a
BMI > 35, where only 4 men and 7 women needed to
be tested in order to yield one new diagnosis of diabetes.
Diabetes testing was much less efficient in other risk
groups, notably younger women who appeared to be
tested at a rate disproportionate to their risk of diabetes.
T h eh i g h e s tN N Sv a l u ei no u rs t u d ya t2 3 9w a s
observed for women in the lowest decile of diabetes of
which 77% underwent testing between 2001 and 2006.
Women with other low risk attributes including having
a BMI less than 23, age under 30, and women who the
CDA would not recommend screening, were also
observed to have a testing rate of 77% at the end of the
Table 1 Baseline characteristics of the cohort
Males Females
Characteristic (N = 11,684) (N = 14,103)
BMI (mean/median) 26.1/25.6 24.9/24.0
Age (mean/median) 44/42 46/44
Age <45, % 56.5 51.9
45≤Age < 65, % 30.8 31.6
Age≥65, % 12.6 16.6
BMI < 23 22.2 39.5
23≤BMI < 25 21.5 17.8
25≤BMI < 30 40.0 27.2
30≤BMI < 35 12.8 9.4
BMI≥35 3.0 4.0
Non-white, % 16.5 16.2
Immigrant, % 30.0 29.6
Hypertension, % 12.0 14.4
Current Smoker, % 24.9 19.1
Heart Disease, % 4.9 5.0
Graduated Post Secondary School, % 61.8 58.7
Low Income, % 5.9 9.0
Rural Residence, % 15.4 14.1
> = 1 Specialist visit year prior, % 33.5 48.2
Median GP visits year prior 2.0 4.0
CDA recommended testing 71.9 73.3
5-year diabetes incidence rate, % 4.7 3.7
SBG Test in 5 years 66.1 80.6
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Males Females
Overall
N
SBG
Screening
Rates N (%)
Diabetes
Incidence
Rate N (%)
NNS Undiagnosed
N (%)
Overall
N
SBG
Screening
Rates N (%)
Diabetes
Incidence
Rate N (%)
NNS Undiagnosed
N( % )
Age
< 30 770,046 338,031
(43.9)
3,775 (0.5) 90 4,813 (0.64) 724,622 530,460
(73.2)
9,258 (1.3) 57 3,389 (0.47)
30-40 932,346 549,356
(58.9)
17,516 (1.9) 31 12,211 (1.31) 878,512 678,356
(77.2)
23,993 (2.7) 28 7,079 (0.81)
40-50 895,685 622,058
(69.5)
37,893 (4.2) 16 16,668 (1.86) 915,611 738,888
(80.7)
26,571 (2.9) 28 6,355 (0.69)
50-60 592,437 488,119
(82.4)
54,358 (9.2) 9 11,617 (1.96) 605,545 527,646
(87.1)
33,802 (5.6) 16 4,990 (0.82)
60-70 352,317 301,598
(85.6)
34,063 (9.7) 9 5,728 (1.63) 425,580 367,952
(86.5)
24,965 (5.9) 15 3,910 (0.92)
70-80 237,503 200,328
(84.4)
27,067 (11.4) 7 5,023 (2.11) 326,074 284,792
(87.3)
24,579 (7.5) 12 3,563 (1.09)
> = 80 80,671 69,634 (86.3) 6,076 (7.5) 11 963 (1.19) 140,307 122,712
(87.5)
6,682 (4.8) 18 958 (0.68)
BMI
< 23 858,877 543,837
(63.3)
17,909 (2.1) 30 10,375 (1.21) 1,585,528 1,224,805
(77.3)
22,181 (1.4) 55 6,533 (0.41)
23-25 830,834 537,390
(64.7)
25,365 (3.1) 21 13,851 (1.67) 715,910 589,129
(82.3)
10,862 (1.5) 54 2,338 (0.33)
25-30 1,545,276 1,051,697
(68.1)
63,206 (4.1) 17 29,664 (1.92) 1,093,914 910,076
(83.2)
56,542 (5.2) 16 11,422 (1.04)
30-35 492,792 335,215
(68.0)
51,068 (10.4) 7 24,006 (4.87) 375,544 318,462
(84.8)
31,460 (8.4) 10 5,639 (1.50)
≥35 117,323 90,112 (76.8) 21,361 (18.2) 4 6,450 (5.50) 159,092 136, 950
(86.1)
18,327 (11.5) 7 2,963 (1.86)
Urban
Yes 595,749 2,199,153
(62.1)
156,774 (4.8) 14 15,103 (0.63) 3,449,416 2,803,812
(81.3)
130,476 (3.4) 21 30,043 (0.87)
No 3,265,256 369,972
(67.4)
23,973 (4.0) 15 23,973 (3.24) 566,835 447,001
(78.9)
19,374 (3.8) 23 5,194 (0.92)
Income
Medium - High
Income
3,307,677 2,212,001
(66.9)
151,223 (4.6) 15 74,906 (2.26) 3,274,131 2,660,077
(81.2)
114,373 (3.5) 23 26,411 (0.81)
Low Income 226,796 150,533
(66.4)
14,931 (6.6) 10 7,564 (3.34) 362,139 292,618
(80.8)
17,314 (4.8) 17 4,113 (1.14)
Missing income 326,533 206,591
(63.3)
14,592 (4.5) 14 8,472 (2.59) 379,781 298,118
(78.5)
18,164 (4.8) 16 4,976 (1.31)
Education (%)
< Than Post-
Secondary
1,463,580 953,241
(65.1)
85,215 (5.8) 11 46,108 (3.14) 2,345,860 1367352
(82.9)
81,053 (4.9) 17 16,733 (1.01)
Post-Secondary
Graduation
2,370,510 1,596,255
(67.3)
94,249 (4.0) 17 46,330 (1.95) 1,649,628 1867019
(79.6)
68, 453 (2.9) 27 17,556 (0.75)
Ethnicity
White 3,221,837 2.089,112
(64.8)
138,556 (4.3) 15 75,126 (2.33) 3,364,092 2,697,355
(80.2)
125,615 (3.7) 21 31,050 (0.92)
Non-white 634,399 471,945
(75.2)
40,345 (6.4) 12 13,460 (2.14) 649,657 552,197
(85.0)
24,134 (3.7) 23 4,255 (0.66)
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(Continued)
Immigrant
Yes 1,158,710 895,326
(77.3)
76,424 (6.6) 12 22,482 (1.94) 1,188,590 1,027,063
(86.4)
52,249 (4.4) 20 8,217 (0.69)
No 2,300,910 1,672,413
(61.9)
103,751 (3.8) 16 63,805 (2.36) 2,825,492 2221610
(78.6)
97,421 (3.5) 23 26,481 (0.94)
CDA
recommended
testing
Yes 2,776,919 2,066,820
(74.4)
174,532 (6.3) 12 59,964 (2.16) 2,943,259 2,471,320
(84.0)
137,070 (4.7) 18 26,176 (0.89)
No 1,084,087 502,305
(46.3)
6,216 (0.6) 81 7,200 (0.66) 1,072,992 779,493
(72.7)
12,380 (1.2) 63 4,661 (0.43)
Hypertension
Yes 464,040 398,018
(85.8)
52,367 (11.3) 8 8,686 (1.87) 578,863 517,314
(89.4)
51,606 (8.9) 10 6,140 (1.06)
No 3,398,054 2,168,513
(64.0)
128,373 (3.8) 17 72,361 (2.13) 3,433,812 2,729,924
(79.5)
98,245 (2.9) 28 25,332 (0.74)
Has Heart
Disease
Yes 190,236 158,9 67
(83.6)
23,433 (12.3) 7 4,609 (2.42) 198,884 176,103
(88.6)
10,431 (5.2) 17 1,349 (0.68)
No 3,670,118 2,409,746
(65.7)
157,314 (4.3) 15 8,228 (0.32) 3,816,102 3,073,446
(80.5)
139,305 (3.7) 22 33,661 (0.88)
GP visits year
prior
0 1,106,642 563,932
(51.0)
38,156 (3.5) 15 36,720 (3.32) 595,001 398,240
(66.9)
14,285 (2.4) 28 7,058 (1.19)
1 to 3 880,234 601,531
(68.3)
36,891 (4.2) 16 17,092 (1.94) 881,194 707,051
(80.2)
22,589 (2.6) 31 5,564 (0.63)
3 to 6 643,173 507,004
(78.8)
36,911 (5.7) 14 9,913 (1.54) 922,366 772,054
(83.7)
42,438 (4.6) 18 8,262 (0.90)
more than 6 610,842 517,983
(84.8)
54,679 (9.0) 9 9,802 (1.60) 1,144,539 1,012,660
(88.5)
59,031 (5.2) 17 7,688 (0.67)
Any specialist
visits year prior
Yes 1,291,364 1,012,569
(78.4)
82,866 (6.4) 12 22,816 (1.77) 1,935,924 1,656,767
(85.6)
85,879 (4.4) 19 14,470 (0.75)
No 2,569,642 1,556,555
(60.6)
97,882 (3.8) 16 63,707 (2.48) 2,080,327 1,594,047
(76.6)
63,971 (3.1) 25 19,515 (0.94)
Current Smoker
Yes 960,272 562,180
(58.5)
30,296 (3.2) 19 21,453 (2.23) 765,308 573,968
(75.0)
27,488 (3.6) 21 9,163 (1.20)
No 2,899,597 2,006,504
(69.2)
150,452 (5.2) 13 66,966 (2.31) 3,248,525 2,675,254
(82.4)
122,362 (3.8) 22 26,220 (0.81)
Deciles of
5-year Diabetes
Risk
1 550,105 169,194
(55.4)
4,887 (0.89) 62 6,144 (1.12) 464,029 340,733
(73.4)
1,424 (0.31) 239 516 (0.11)
2 329,707 242,041
(51.3)
2,134 (0.65) 79 1,110 (0.34) 391,905 284,318
(72.5)
2,587 (0.66) 110 978 (0.25)
Wilson et al. BMC Public Health 2010, 10:506
http://www.biomedcentral.com/1471-2458/10/506
Page 6 of 12Table 2 Univariate comparisons of diabetes risk factors and screening, diabetes incidence, and yield of screening
(Continued)
3 477,327 256,151
(50.7)
2,680 (0.56) 90 2,458 (0.51) 433,997 337,126
(77.7)
4,609 (1.1) 73 1,327 (0.31)
4 430,093 263,288
(59.6)
5,483 (1.3) 47 3,549 (0.83) 568,618 440,384
(77.4)
10,316 (1.8) 43 2,982 (0.52)
5 348,449 254,219
(75.6)
13,566 (3.9) 19 4,959 (1.42) 375,633 297,289
(79.1)
12,192 (3.3) 24 3,264 (0.87)
6 383,153 292,415
(66.3)
17,797 (4.6) 14 6,481 (1.69) 414,068 352,650
(85.2)
12,568 (3.0) 28 2,194 (0.53)
7 379,107 254,447
(77.1)
18,386 (4.9) 16 7,791 (2.06) 306,102 252,960
(82.6)
17,859 (5.8) 14 3,796 (1.24)
8 317,279 247,118
(80.2)
22,045 (7.0) 12 5,847 (1.85) 372,234 325,893
(87.6)
22,011 (5.9) 15 3,089 (0.83)
9 314,169 269,534
(78.7)
30,238 (9.6) 8 5,579 (1.78) 325,268 275,806
(84.8)
24,374 (7.5) 11 4,497 (1.38)
10 331,619 169,194
(81.3)
63,531 (19.2) 4 40,606 (12.24) 364,398 327,766
(89.9)
41,911 (11.5) 8 4,579 (1.26)
Overall 3,861,006 2,569,124
(66.5)
180,747 (4.7) 14 92,277 (2.39) 4,016,251 3,250,814
(80.9)
149,850 (3.7) 22 34,793 (0.87)
Table 3 Unadjusted and adjusted hazard ratios and 95% (bootstrapped) confidence intervals by sex
MALES FEMALES
UNADJUSTED ADJUSTED UNADJUSTED ADJUSTED
Variable Hazard Ratio 95% CI Hazard Ratio 95% CI Hazard Ratio 95% CI Hazard Ratio 95% CI
Age
< 30 1.00 ref 1.00 ref 1.00 ref 1.00 ref
30-40 1.53 (1.33, 1.77) 1.41 (1.22, 1.63) 1.17 (1.07, 1.29) 1.12 (1.02, 1.24)
40-50 2.08 (1.82, 2.37) 1.93 (1.69, 2.21) 1.34 (1.22, 1.47) 1.32 (1.19, 1.46)
50-60 3.24 (2.82, 3.71) 2.82 (2.46, 3.24) 1.77 (1.60, 1.96) 1.65 (1.48, 1.83)
60-70 4.19 (3.62, 4.86) 3.43 (2.95, 3.98) 1.80 (1.61, 2.01) 1.64 (1.46, 1.84)
70-80 4.20 (3.54, 4.98) 3.13 (2.61, 3.77) 2.07 (1.86, 2.30) 1.81 (1.62, 2.03)
> = 80 4.70 (3.85, 5.74) 3.19 (2.56, 3.98) 2.22 (1.92, 2.58) 1.86 (1.54, 2.26)
BMI (continuous) 1.01 (1.01, 1.02) 1.01 (1.00, 1.02) 1.02 (1.02,1.03) 1.01 (1.01, 1.02)
Hypertension (Yes) 2.12 (1.95, 2.32) 1.27 (1.16, 1.39) 1.59 (1.49,1.70) 1.12 (1.03, 1.22)
Income
Med-High 1.00 ref 1.00 ref 1.00 ref 1.00 ref
Low 0.96 (0.87, 1.14) 0.86 (0.75, 0.98) 1.02 (0.93, 1.13) 0.92 (0.84, 1.02)
Not Stated 0.93 (0.79, 1.08) 0.93 (0.80, 1.08) 0.94 (0.84, 1.06) 0.88 (0.79, 0.98)
Immigrant 1.56 (1.43, 1.70) 1.26 (1.15, 1.37) 1.38 (1.28, 1.48) 1.24 (1.15, 1.34)
Non-white ethnicity 1.34 (1.20, 1.50) 1.38 (1.23, 1.55) 1.23 (1.11,1.36) 1.19 (1.06, 1.33)
Number of GP visits year prior
0 1.00 ref 1.00 ref 1.00 ref 1.00 ref
1-3 1.47 (1.35,1.59) 1.42 (1.31, 1.55) 1.31 (1.19, 1.44) 1.31 (1.19, 1.44)
3-6 2.02 (1.85, 2.20) 1.72 (1.57, 1.87) 1.53 (1.42, 1.67) 1.52 (1.40, 1.65)
> = 6 2.86 (2.59, 3.17) 2.13 (1.90, 2.38) 1.96 (1.80, 2.13) 1.81 (1.66, 1.98)
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Page 7 of 12study period. Table 2 displays the variation in the NNS
estimates both within and between different sub-groups.
For example, there was little difference in the NNS esti-
mates for some subgroups such as urban residence as
evidenced by a NNS of 14 for urban and a NNS of 15
for non-urban men; ethnicity with an observed NNS of
21 for white women and a NNS of 23 for women of
non-white ethnicity; and similar NNS estimates for self-
reported immigrant and non-immigrant status within
each gender. In contrast, there were other subgroups
w h e r et h ed i f f e r e n c e si nN N Sw e r em o r ea p p a r e n t
within the subgroup such as BMI, self-reported hyper-
tension, self-reported heart disease and the summary
variable indicating whether the CDA would recommend
testing. For example, the NNS estimate for men recom-
mended to be screened by the CDA is 12, in contrast to
Figure 1 SBG testing (%) and observed diabetes incidence (%) by decile of five-year diabetes risk for males from 2001-2006.
Figure 2 SBG testing (%) and observed diabetes incidence (%) by decile of five-year diabetes risk for females from 2001-2006.
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Page 8 of 12a NNS of 81 for men not recommended to be screened
in accordance with the CDA guidelines
Population Effectiveness of Diabetes Testing
At the end of the study, we estimated 1.4% of Ontario
adults (127,100 cases) had undiagnosed diabetes. Among
the male cohort, 2.4% were estimated to have undiag-
nosed diabetes comprising three-quarters (92,300) of the
total number of undiagnosed cases. Among men, the
most common groups remaining with undetected dia-
betes were those in the tenth decile of risk (12.2%), men
with BMIs > 35 (5.5%) and BMIs 30-35 (4.9%), low
income (3.3%), and those with no GP visits in the year
preceding CCHS survey completion (3.3%). Among
women, there were an estimated 34,800 cases of undiag-
nosed diabetes at the end of the study period (0.9% of
all women). The groups with the highest percentage of
undiagnosed diabetes among females were those with
BMI >35 (1.9%), BMI 30-35 (1.5%), ninth decile of risk
for diabetes (1.4%), those refusing to self-report income
(1.4%), and tenth decile of risk for diabetes (1.3%).
We found that groups with high rates of screening
still maintained high proportions of undetected diabetes.
Men in the tenth decile of diabetes risk had the highest
percentage of undiagnosed diabetes at 12.2% despite a
screening rate of 81%. The highest rate of undiagnosed
diabetes among women was found among those with
BMIs >35 at 1.9%, despite an 86% screening rate. Figure
3 displays the distribution of undiagnosed cases of dia-
betes by quintile of diabetes risk. Among men, 53% of
all undiagnosed diabetes is estimated to occur among
men in the highest quintile of diabetes risk. Due to the
higher rates of screening observed among women, only
one-third of undiagnosed diabetes is found in the high-
est quintile of diabetes risk with greater representation
of undiagnosed diabetes in lower quintiles of risk.
Discussion
This population-based study documents a high degree of
serum blood glucose testing in the community-dwelling
population of Ontario adults without diabetes. Between
2001 and 2006, 80% of women and 66% of men aged 20
and older underwent glucose testing. In addition, per-
sons with risk factors for diabetes, such as older age,
high BMI, hypertension and non-white ethnicity, were
appropriately tested significantly more often. Screening
in Ontario appears to be largely efficient, with a yield of
testing that results in 14 men and 22 women requiring
glucose testing to yield one new diagnosis of diabetes,
respectively. Glucose testing is most efficient for groups
with elevated BMIs with NNS values as low as 4, and
least efficient for low risk women who appear to
undergo a disproportionate amount of testing relative to
their risk of diabetes. Despite high rates of testing in
higher risk groups, undiagnosed diabetes remains preva-
lent, especially among men wherein three-quarters of all
undiagnosed diabetes is found. The highest rates of
undiagnosed diabetes were found among those in the
highest deciles of diabetes risk, those with elevated
BMIs, and among men, low-income status, despite test-
ing rates as high as 80%.
Despite high levels of screening and a publicly funded
health care system with universal access, an estimated
28% of all diabetes in the province of Ontario remains
undiagnosed. This compares similarly with the results of
the most recent NHANES surveys in the United States
where the percentage of undiagnosed diabetes was
found to be 30.1% in the 1999-2002 survey [4] and
34.6% in the 1988-1994 survey [5]. In Ontario, men are
more likely to be undiagnosed than women. This
reflects both a lower rate of testing and a higher inci-
dence of diabetes in men relative to women. Barriers to
undergoing diabetes testing can be presumed to operate
at the level of the individual, clinic and the health sys-
tem. In our multivariate analysis we found that men
with low incomes and women who did not self-report
income were significantly less likely to under SBG test-
ing, after controlling for other variables, including BMI.
These findings suggest that not only is low income sta-
tus a risk factor diabetes [28], but it appears also to be a
Figure 3 Distribution of undiagnosed diabetes by quintile of diabetes risk for men and women.
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Page 9 of 12risk factor for having undiagnosed diabetes, even in a
system with universal access to publicly funded health
care services. This suggests that a strategy beyond the
dissemination of clinical practice guidelines for diabetes
testing is required to address undiagnosed diabetes in
low income populations.
The analyses presented here have several implications
for diabetes screening. This study shows that, in general,
clinicians’ screening behaviour increases in proportion
to the risk of diabetes, with increasing proportions of
individuals tested with increasing 5-year risk of diabetes.
However, at the extremes of risk there appears to be a
mis-match between screening and diabetes risk.
Low-risk individuals, in particular women, undergo a
disproportionate amount of screening in relation to
their low-risk status resulting in large estimates for the
NNS, while the screening rates of higher-risk individuals
could be increased further, in order to further reduce
the burden of undiagnosed diabetes. This finding could
be a reflection of a healthy user effect. However, it is
important to note that our methodology for the concep-
tualization of efficiency, NNS, may be over-estimated in
lower risk individuals and be under-estimated in higher-
risk individuals owing to the fact that the ODD is used
for a determination of diabetes status and is likely to
have a greater false positive rate associated with low risk
individuals due to the lower prevalence of diabetes. We
are not aware of any previous publication that has docu-
mented the population-level rates of diabetes screening
to which our data can be compared; however, some stu-
dies have reported on the frequency and yield of testing
within a single health care organization [29]. Our data
compare similarly with a retrospective study from a
large Health Maintenance Organization which found a
screening rate of 73% among women and 66% among
men after three years [29]. However, this study exam-
ined screening only among adults aged >45 years, for
whom both the CDA and the American Diabetes Asso-
ciation recommend routine testing. Our data examined
diabetes screening in adults over the age of 20, which
includes a large number of adults that typically would
not be recommended to undergo diabetes screening,
unless significant risk factors are present. We found that
the rates of screening in Ontario among those aged 40
and over were relatively unchanged from our overall
estimates, with 84% of women and 63% of men tested
between 2001 and 2006.
Other investigators have conceptualized NNS in the
same way and have utilized the measure to examine the
yield of diabetes screening in Japan [30]. However, the
yield of screening was examined for subjects presenting
for a periodic health examination within a hospital set-
ting, rather than a population based analysis [30]. The
NNS values found in that study were 16 for men and 32
for women. In our population-based cohort of adult
Ontarians we found that 14 men and 22 women
required screening in order to yield one incident diagno-
sis of diabetes, respectively. The concept of ‘number
needed to be screened’ was originally developed by
Rembold in 1998 to define a summary statistic analo-
gous to the ‘number needed to treat’ that would allow
for the comparison of different screening strategies on
mortality reduction [31]. Rembold used mortality data
from randomized controlled trials (RCTs) of screening
interventions and defined number needed to screen as
“t h en u m b e ro fp e o p l et h a tn e e dt ob es c r e e n e dt op r e -
vent one death”. Given the lack of RCT in the area of
diabetes screening, and the paucity of evidence demon-
strating that earlier detection of diabetes results in mor-
tality reduction [18] we instead defined NNS in relation
to the yield of incident diabetes diagnoses over a five-
year period.
Most of what is currently known about the prevalence
of undiagnosed diabetes (screening effectiveness) comes
from data collected as part of cross-sectional population
health surveys which compare biological markers, such
as blood glucose testing, with self-reported health states
including diabetes. Here we demonstrate that surveil-
lance of ‘undiagnosed’ diabetes can be accomplished
with the use of longitudinal population-based adminis-
trative health data that include information on testing
and diabetes diagnoses. This analytic approach allows
current screening practices to be evaluated from the
three perspectives of population coverage, efficiency and
effectiveness. Surveys with biologic markers typically
report undiagnosed DM as a proportion of total cases of
diabetes (diagnosed and undiagnosed). The diabetes
database used in our study provides population esti-
mates of diabetes diagnosis [24], which can be combined
with the findings of this study to report undiagnosed
diabetes cases as a proportion of the estimated total of
diabetes in Ontario. Among men, the estimated 92,300
cases of undiagnosed diabetes represent 16% of the total
burden of diabetes over the same time period (563,000
cases of prevalent and newly diagnosed cases). Among
women, there were an estimated 34,800 cases of undiag-
n o s e dd i a b e t e sa tt h ee n do ft h es t u d yp e r i o d ,c o m p r i s -
ing 7.8% of the total burden of diabetes (443,000 cases
of prevalent and newly diagnosed diabetes).
Surveillance of diabetes is a necessary first step
towards its prevention and control [1,32]. However,
there are many challenges associated with surveillance
of diabetes and other chronic diseases that fall outside
of traditional surveillance mechanisms that currently
exist for communicable diseases and cancer [32]. Novel
models of diabetes surveillance are being developed,
including the New York City Department of Health and
Mental Hygiene’s A1C Registry which was initiated in
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Page 10 of 122006 [33]. However, even with creative techniques the
capture of undiagnosed diabetes remains a major chal-
lenge to robust diabetes surveillance. The analytic
approach presented here allows for an estimation of
undiagnosed diabetes, in addition to other important
population attributes of current screening practices with
the use of administrative health data sources alone.
The strengths of our study include the use of popula-
tion-based administrative data linked to a population
health survey to examine the time to first serum blood
glucose test in a cohort of community dwelling adults in
Ontario. Individuals with diabetes were identified and
removed from our analysis with the use of a validated
diabetes database [24] and laboratory data were linked
to individuals with a unique identifier. However, there
are some important limitations that deserve mention.
First, we were not able to differentiate between fasting
and random serum blood glucose tests using our data.
Since only fasting blood glucose testing is recommended
for the diagnosis of diabetes in asymptomatic indivi-
duals, our analysis provides an estimation of the degree
of screening for diabetes. Other investigators examining
diabetes screening have found that serum blood glucose
is the most common test ordered for screening [19,29].
Due to our use of administrative health data (OHIP bill-
ings) to estimate diabetes case detection, our data cap-
tures testing in asymptomatic individuals [screening] as
well as testing in symptomatic individuals (diagnosis).
However, given that most individuals are asymptomatic
at the time of diabetes diagnosis [11], the majority of
testing captured in this study is likely to represent
opportunistic screening. Second, our estimates of dia-
betes were derived from a registry that is associated
with a 14% false negative rate, which confers some risk
of misclassification. Third, although we have captured
all diabetes-related laboratory services billed to OHIP,
we were not able to capture lab tests carried out within
the global budget of hospital inpatient services. How-
ever, this limitation at most resulted in an underesti-
mate of the current degree of diabetes testing in
Ontario. Finally, the survival analysis methodology
employed in this study involved following individuals
until the date of respondents’ first diabetes laboratory
test or diabetes diagnosis. However, this limited our
ability to examine the relationship between the fre-
quency of testing and future diabetes risk. This is an
important area for future investigations.
Conclusions
Diabetes screening in Ontario is common with screen-
ing rates of 80% among women and 66% among men
over a five year time period, and is largely efficient. The
NNS, our measure of screening efficiency, is 14 for men
and among women is 21 which likely reflects that
clinicians are appropriately testing individuals with risk
factors for diabetes and that diabetes testing is easily
accomplished with a simple, readily available and inex-
pensive test. Screening is least efficient in low-risk
women who are commonly screened, and screened dis-
proportionately in relation to many moderate and high
risk groups. Despite high rates of screening in Ontario,
undiagnosed diabetes among men remains clustered
among those at highest risk for diabetes suggesting a
disproportionately low amount of testing in relation to
risk. Furthermore, low income men are less likely to
undergo testing. To further improve the overall popula-
tion effectiveness of screening, higher risk individuals
may need specific targeting which may require programs
that seek to reduce the barriers to accessing traditional
screening in primary care and other traditional health
care settings.
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